Connected Thinking

Leading Voices

Latest News

ASCO: New Study Provides Hope For Patients With HER2 ‘Low’ Breast Cancer

HER2 “low” may become a new commonly classified subtype of breast cancer.

Learn More

ASCO: Updated Guidelines on Biomarkers for Early-Stage Breast Cancer

The new guidelines now recommend the use of Breast Cancer Index (BCI) to assess the risk of breast cancer recurrence in some patients.

Learn More

ASCO: Study Indicates Panitumumab Works Best For Patients With One Type Of Metastatic Colorectal Cancer

A new trial is the first to compare the effectiveness of different targeted drug therapies as part of chemo treatments for a certain kind of metastatic colorectal cancer (left sided).

Learn More

Treating Multiple Myeloma in the Second Line: Which Option Should You Choose?

After first-line multiple myeloma treatment, which strategy is best for second-line therapy?

Learn More

Bispecific Antibodies Challenge CAR T-Cell Therapy as Multiple Myeloma Treatment Contender

The latest buzzword in multiple myeloma is bispecifics. This off-the-shelf treatment is proving to be an attractive option for patients who can't wait for CAR T-cell therapy.

Learn More

Selinexor Worth Prescribing, with Proper Supportive Care

Prescribing the right dose of selinexor and navigating side effects have proved challenging in the treatment of patients with multiple myeloma.

Learn More

How Do Two CAR T-Cell Therapies Stack Up When Comparing Results Across Trials?

Which of two investigational CAR T-cell therapies, vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), has the advantage?

Learn More

Black Participation in Clinical Trials Is Imperative to Reduce Racial Disparities in Multiple Myeloma

By Kayle Waterhouse African Americans must be properly represented in clinical trials to ensure equal treatment for multiple myeloma and other cancers, top oncologists told SurvivorNet Connect.  Dr. Ajay Nooka, a hematologist-oncologist at the Winship Cancer Institute, says Blacks are underrepresented in clinical trials. He states that “20% of the patients that we treat for […]

Learn More